X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    FDA Accepts BLA for Recommended

    FDA Accepts BLA for Recommended Biosimilar to Simponi

    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    FDA Accepts BLA for Recommended

    FDA Accepts BLA for Recommended Biosimilar to Simponi

    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Clinical Trials

AzurRx expands trial of drug for Covid-19-linked GI infections to Ukraine

Content Team by Content Team
12th August 2021
in Clinical Trials, Drug Development, News
Charities Pay $6 Million to Settle Medicare Kickback Allegations in Pharma Probe

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

AzurRx BioPharma has expanded the ongoing Phase II RESERVOIR clinical trial of FW-1022 for the treatment of Covid-19-related gastrointestinal (GI) infections in Ukraine.

The company has concluded site initiation visits and added five new trial centres in the country.

FW-1022 is an oral tablet that consists of micronised niclosamide and is designed to carry increased concentrations of the drug directly to the GI tract.

AzurRx said that the GI tract is a likely reservoir for Covid-19 recurrence and faecal spread of SARS-CoV-2 since the entry receptor for the virus, ACE-2, is increasingly expressed on GI cells.

Niclosamide is a US Food and Drug Administration (FDA)-cleared prescription small molecule drug with anti-helminthic activity, as well as anti-inflammatory and anti-viral properties.

In April, AzurRx started the Phase II RESERVOIR trial to evaluate FW-1022 in patients with Covid-19-linked GI infection.

The two-part, two-arm, placebo-controlled trial will analyse the safety of FW-1022 and its efficacy to clear the SARS-CoV-2 virus from the GI tract as primary goals.

The rate of faecal SARS-CoV-2 clearance, assessed by RT-PCR, in subjects receiving niclosamide versus placebo for up to six weeks is the trial’s primary efficacy goal.

AzurRx expects top-line results from the trial in the first quarter of next year.

Furthermore, these long-term observation data could signify the potential of niclosamide to improve symptoms of long-haul Covid-19.

AzurRx BioPharma chairman, CEO and president James Sapirstein said: “Niclosamide represents an important advance in the fight to help Covid-19 patients overcome the debilitating and often overlooked effect the virus can have on the GI system.

“The addition of new trial sites in Ukraine provides enhanced opportunity to enrol patients in a country where less than 5% of the population is fully vaccinated for Covid-19.”

Contract research organisation PPD is managing the RESERVOIR trial.

AzurRx is currently developing another micronised niclosamide formulation, FW-420, for the treatment of immune checkpoint inhibitor-associated colitis.

 

Previous Post

Moderna and Canada Announce Collaboration to Bring mRNA Manufacturing to Canada

Next Post

Valneva Initiates Further Phase 3 Clinical Trial for its COVID-19 Vaccine Candidate

Related Posts

FDA Accepts BLA for Recommended
FDA Approvals

FDA Accepts BLA for Recommended Biosimilar to Simponi

22nd July 2025
Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
ChiRhoClin LogiCare3PL Partners for Drug Distribution
News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

21st July 2025
Emerging Oral Small Molecule Drugs
Drug Development

Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
Next Post
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

Valneva Initiates Further Phase 3 Clinical Trial for its COVID-19 Vaccine Candidate

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In